Mar 27 |
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference
|
Mar 25 |
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic
|
Mar 7 |
Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript
|
Mar 7 |
Plus Therapeutics Full Year 2023 Earnings: Beats Expectations
|
Mar 6 |
Q4 2023 Plus Therapeutics Inc Earnings Call
|
Mar 6 |
Plus Therapeutics, Inc. (PSTV) Q4 2023 Earnings Call Transcript
|
Mar 5 |
Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates
|
Mar 5 |
Plus Therapeutics GAAP EPS of -$4.24 misses by $3.07
|
Mar 5 |
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
|
Mar 5 |
Earnings Scheduled For March 5, 2024
|